Clinical trials: Capecitabine
RECTAL CANCER
Capecitabine Plus Concomitant Radiation Therapy Followed by Durvalumab as Preoperative Treatment in Rectal Cancer
This is a prospective phase II, open label, single arm, multi-centre study to evaluate activity of an innovative sequence on capecitabine plus concomitant radiation therapy followed by durvalumab in patients with operable rectal…
- Trial name
- PANDORA (NCT04083365)
- Testing
- Capecitabine, Radiotherapy, Durvalumab
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- AUSL Romagna Rimini
Recurrent Pituitary Adenomas
Capecitabine and Temozolomide for Treatment of Recurrent Pituitary Adenomas
This is an open label study to assess the efficacy of capecitabine (CAP) and temozolomide (TMZ) in recurrent pituitary adenomas. There will be a safety run-in of at least three patients to establish any dose limiting toxicities.
- Trial name
- TMZ-Cap (NCT03930771)
- Testing
- Capecitabine, Temozolomide
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Weill Medical College of Cornell University
Colo-rectal Cancer, PD-1 Inhibitor
Akkermansia Probiotics Plus Anti-PD-1 Monoclonal Antibody in MSS/pMMR Advanced Colorectal Cancer
The investigators propose to conduct a single-center, single-arm, Phase I clinical study to explore the safety and feasibility of Akkermansia probiotics combined with anti-PD-1 monoclonal antibody in patients with MSS/pMMR…
- Conditions
- Colo-rectal Cancer, PD-1 Inhibitor, Akkermansia Muciniphila
- Trial name
- NCT06865521
- Testing
- Akkermansia Probiotics
- Where
- 2 sites in China
- Volunteers
- 22 people
- Sponsor
- West China Hospital
Biliary Tract Neoplasms, Cholangiocarcinoma
Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)
Background: Biliary tract cancers are rare but they are serious. Researchers want to see if a certain drug helps the immune system fight cancer cells. The drug is called pembrolizumab.
- Conditions
- Biliary Tract Neoplasms, Cholangiocarcinoma, Bile Duct Cancer, Liver Cancer
- Trial name
- NCT03111732
- Testing
- Pembrolizumab (MK-3475), Oxaliplatin, Capecitabine
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer
wXELIRI Versus FOLFIRI Regimen in the Treatment of Advanced Colorectal Cancer Patients
The aim of this study is to compare weekly-XELIRI(wXELIRI) regimen versus FOLFIRI regimen in the treatment of advanced colorectal cancer patients.
- Trial name
- NCT01736904
- Testing
- wXELIRI regimen, FOLFIRI regimen
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Fudan University
Metastatic Breast Cancer, Colorectal Cancer
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
The purpose of this study is to evaluate the efficacy of the implementation of an educational program on adherence to capecitabine alone or in combination to lapatinib.
- Trial name
- ProMETheX (NCT01847599)
- Testing
- Educational Intervention to enhance the adherence of Patient treated by capecitabine +/- Lapatinib
- Where
- France
- Volunteers
- 65 people
- Sponsor
- Centre Jean Perrin
Colorectal Cancer Liver Metastases (CRLM), Colorectal Cancer
Hepatic Arterial Infusion of Liposomal Irinotecan Plus Oxaliplatin and Capecitabine as Adjuvant Therapy for Colorectal Cancer Liver Metastases
This is a prospective, single-center, single-arm exploratory clinical study designed to evaluate the efficacy and safety of hepatic arterial infusion of liposomal irinotecan combined with systemic oxaliplatin and capecitabine as…
- Conditions
- Colorectal Cancer Liver Metastases (CRLM), Colorectal Cancer, Liver Metastasis
- Trial name
- NCT07570914
- Testing
- Liposomal Irinotecan, Oxaliplatin, Capecitabine
- Volunteers
- 28 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Colorectal Cancer, Gastric Cancer
Study of TKI 258 in Combination With Xeloda and Oxaliplatin in Advanced Colorectal and Gastric Cancer
Standard "3+3" dose escalation design of TKI258/XELOX in advanced gastric/gastro-oesophageal and colorectal cancer.
- Trial name
- NCT02720926
- Testing
- Xeloda,, Oxaliplatin, TKI258
- Where
- Singapore
- Volunteers
- 3 people
- Sponsor
- National Cancer Centre, Singapore
Adenocarcinoma of Small Intestine, Appendix Carcinoma
Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma
To explore the safety and efficacy of Surufatinib and Sintilimab in Combination With Capecitabine in Patients With Previously Treated Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma : a Single-arm, a…
- Conditions
- Adenocarcinoma of Small Intestine, Appendix Carcinoma, Metastatic
- Trial name
- NCT05472948
- Testing
- Surufatinib, Sintilimab, Capecitabine
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Sun Yat-sen University
Advanced Breast Cancer
Metronomic Oral Chemotherapy With Cyclophosphamide, Capecitabine and Vinorelbine in Metastatic Breast Cancer Patients
This is a phase II study assessing the activity and safety of metronomic chemotherapy with cyclophosphamide and capecitabine and vinorelbine in advanced breast cancer patient in four different cohort of patients: 1.
- Trial name
- VEX (NCT04304352)
- Testing
- Vinorelbine, Capecitabine, Cyclophosphamide
- Where
- Italy
- Volunteers
- 162 people
- Sponsor
- European Institute of Oncology
Liver Cancer
A Study of SH006 Injection Combination Therapy in Patients With Advanced Solid Tumors
To evaluate the safety and tolerability of the combination therapy of SH006 injection in patients with advanced solid tumors
- Trial name
- NCT07362264
- Testing
- SH006
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Nanjing Sanhome Pharmaceutical, Co., Ltd.
Solid Tumors, Non-Small Cell Lung Cancer
Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors
HS-20117 is a fully-human EGFR-MET immunoglobulin G1(IgG1)-like bispecific antibody. The purpose of study is to evaluate the safety, tolerability, efficacy, PK profile and immunogenicity of HS-20117 in combination with other…
- Conditions
- Solid Tumors, Non-Small Cell Lung Cancer, Colorectal Cancer
- Trial name
- HS-20117 (NCT06621563)
- Testing
- HS-20117 combined HS-20093, HS-20117 combined Platinum-containing chemotherapy, HS-20117 combined HS-20093 and 5-FU
- Where
- China
- Volunteers
- 780 people
- Sponsor
- Hansoh BioMedical R&D Company
Breast Cancer
A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America
A Prospective, Multicenter, Non-Interventional Study of Primary Data Collection, Designed to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcomes in Patients with Breast Cancer in Latin America.
- Trial name
- NCT04158258
- Testing
- Bevacizumab, Trastuzumab, Ado-trastuzumab emtamsine
- Where
- 30 sites in Argentina, Brazil and 8 more
- Volunteers
- 2,907 people
- Sponsor
- Hoffmann-La Roche
Unspecified Adult Solid Tumor, Protocol Specific
Capecitabine, Irinotecan, and Oxaliplatin in Treating Patients With Metastatic Cancer
RATIONALE: Drugs used in chemotherapy, such as capecitabine, irinotecan, and oxaliplatin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00544063
- Testing
- irinotecan hydrochloride, oxaliplatin
- Where
- France
- Volunteers
- 33 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Colon Adenocarcinoma, Rectal Adenocarcinoma
Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer
This phase I/II trial studies the side effects and best dose of nintedanib when given together with capecitabine and to see how well they work in treating patients with colorectal cancer that has not responded to previous…
- Conditions
- Colon Adenocarcinoma, Rectal Adenocarcinoma, Recurrent Colon Carcinoma, Recurrent Rectal Carcinoma
- Trial name
- NCT02393755
- Testing
- Capecitabine, Laboratory Biomarker Analysis, Nintedanib
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- Roswell Park Cancer Institute
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Zanidatamab Combined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positive (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Phase II Open-Label Study
This is a phase II open-label study to evaluate the efficacy and safety of zanidatamab combined with chemotherapy as neoadjuvant/conversion therapy in patients with HER2-positive (IHC 3+ or IHC 2+) locally advanced or metastatic…
- Conditions
- Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, HER2-positive Gastric Cancer
- Trial name
- NCT07685704
- Testing
- Zanidatamab, Oxaliplatin, Capecitabine
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Zhifeng Zhao, PhD
Gastric or Esophagogastric Junction Adenocarcinoma
PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer
This multicenter, randomized, double-blind phase III study intends to recruit about 878 patients, including PD-L1 positive 660 patients, who have received radical gastrectomy (R0 resection, D2 or more extended lymphadenectomy)…
- Trial name
- NCT05180734
- Where
- 71 sites in China
- Volunteers
- 878 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Neoplasms
Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid Tumor
To determine the best dose of this investigational agent AG-013736 in combination with various standard of care treatments for advanced solid tumors.
- Trial name
- NCT00454649
- Testing
- Axitinib + Paclitaxel + Carboplatin (Cohort 1), Axitinib + Paclitaxel + Carboplatin (Cohort 2), Axitinib + Paclitaxel + Carboplatin (Cohort 3)
- Where
- 13 sites in United States, Poland and 1 more
- Volunteers
- 102 people
- Sponsor
- Pfizer
Stage III Esophageal Squamous Cell Carcinoma, Stage II Esophageal Squamous Cell Carcinoma
Chemoradiotherapy of Capecitabine With or Without Oxaliplatin Versus Cisplatin-5-FU for Esophageal Squamous Cancer
A three-arm Phase III trial was started in Oct. 2014. Definitive chemoradiotherapy with cisplatin plus 5-fluorouracil is the standard in Western countries in esophagus cancer.
- Trial name
- CRTCOESC (NCT02025036)
- Testing
- Capecitabine(Aibin), Oxaliplatin(Aiheng), Radiotherapy
- Where
- China
- Volunteers
- 249 people
- Sponsor
- The First Affiliated Hospital of Henan University of Science and Technology
Colorectal Cancer
Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status
The aim of this trial is to assess the feasibility of EREG/AREG assessment as a clinical diagnostic standard, used to guide clinical decision making in right-PTL, RAS-wt aCRC.
- Trial name
- ARIEL-ENGIC (NCT07094893)
- Testing
- Cetuximab (EGFR inhibitor), Bevacizumab, Irinotecan (CPT-11)
- Volunteers
- 280 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.